Validation of the Melanoma Institute of Australia's Sentinel Lymph Node Biopsy Risk Prediction Tool for Cutaneous Melanoma.
Sainiteesh MaddineniMatthew P DizonVijaytha MuralidharanLexi A YoungJohn B SunwooFred M BaikSusan M SwetterPublished in: Annals of surgical oncology (2024)
The Calculator generally underestimated SLN positivity risk, including assessment in patients who would be counseled to forego SLNB based on a predicted risk lower than 5%. Recognition of the tool's current limitations emphasizes the need to refine it further for use in medical decision-making.